October 23rd 2024
During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
September 20th 2024
September 19th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Approval Sought for Beti-Cel to Treat B-Thalassemia Requiring Transfusions
September 22nd 2021A biologics license application has been submitted to the FDA for betibeglogene autoemcel gene therapy for the treatment of adult, adolescent, and pediatric patients with B-thalassemia who require regular blood cell transfusions.
Read More
FDA Grants Priority Review to Abatacept to Prevent Moderate to Severe Acute GVHD
August 23rd 2021The FDA has accepted the supplemental biologics license application for abatacept and granted it priority review for the prevention of moderate to severe acute graft versus host disease in patients 6 years of age and older receiving unrelated donor hematopoietic stem cell transplantation.
Read More
FDA Grants Fast Track Designation to Novel Asparaginase Therapy for ALL Subset
July 30th 2021Fast track designation has been granted by the FDA to eryaspase for the treatment of patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.
Read More
FDA Breakthrough Therapy Designation Granted to Venetoclax/Azacitidine for Treatment-Naïve MDS
July 21st 2021The FDA has granted breakthrough therapy designation to the combination of venetoclax and azacitidine for the treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes.
Read More
First Patient Dosed in LAVA-051 Hematologic Malignancy Trial
July 19th 2021The first patient has been dosed in the phase 1/2a clinical trial, designed to evaluate LAVA-051- a gamma-delta bispecific gamma-delta T cell engager that activates Vγ9Vδ2 T cells and type 1 natural killer T cells-in those with chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.
Read More
Clinical Trial Matching Service in Hematologic Cancers Mitigates Barriers to Enrollment
July 18th 2021A national, telephone-based nurse navigator-led service model that aimed to reduce barriers to clinical trial participation among patients with a blood cancer and identified patient demographic and clinical characteristics associated with enrollment was shown to mitigate modifiable barriers to trial enrollment.
Read More
FDA Lifts Partial Clinical from Study of RVU120 in Relapsed/Refractory AML and MDS
July 15th 2021The FDA has lifted its partial clinical hold on a phase 1B study of RVU120, which is an investigation of the agent for the treatment of patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Read More
For patients who relapsed on their prior therapy and have triple-refractory multiple myeloma, selecting the best next-line of therapy is an important decision for their disease outcome. During a Targeted Oncology Case-Based Roundtable event, Peter Forsberg, MD, discussed this topic with a group.
Read More
FDA Grants Fast Track Designation to SNDX-5613 for R/R MLLr and NMP1-Mutant Acute Leukemias
June 28th 2021The FDA has granted fast track designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias who harbor a mixed lineage leukemia rearranged or nucleophosmin mutation.
Read More